Acute Heart Failure

1. Clinical Overview

Summary

Acute Heart Failure (AHF) is a clinical syndrome characterized by the rapid onset or worsening of symptoms and/or signs of heart failure (HF), necessitating urgent medical evaluation and therapy. It remains a leading cause of hospitalization in adults over 65 and is associated with significant morbidity and a high risk of readmission. AHF may represent a de novo presentation or, more commonly, an acute decompensation of chronic heart failure (ADHF).

The clinical presentation is heterogenous but typically involves signs of fluid overload (congestion) and, in more severe cases, reduced cardiac output (peripheral hypoperfusion). Management is prioritized into three phases: the immediate "emergency" phase (hemodynamic stabilization), the "diagnostic" phase (identifying the clinical profile and precipitants), and the "pre-discharge" phase (optimization of Guideline-Directed Medical Therapy, GDMT). The "Wet/Dry" vs "Warm/Cold" classification is the cornerstone of initial therapeutic decision-making.

Key Facts

• Incidence: Over 1 million hospitalizations annually in the US and Europe.
• Pathophysiology: Driven by a "vicious cycle" of neurohormonal activation, cardiomyocyte injury, and fluid redistribution.
• Clinical Profile: > 95% of patients are "Wet" (congested); ~25% are "Cold" (hypoperfused).
• Gold Standard Investigation: BNP/NT-proBNP for exclusion; Transthoracic Echocardiogram for structural characterization.
• First-line Treatment: Intravenous loop diuretics (Furosemide/Bumetanide) are the mainstay for congested patients.
• The "CHAMPIT" Mnemonic: Essential for identifying rapidly reversible precipitants (ACS, Hypertensive crisis, Arrhythmia, Mechanical cause, PE, Infection, Tamponade).

Clinical Pearls

The "B-Line" Pearl: Point-of-care lung ultrasound is more sensitive than chest X-ray for pulmonary congestion. The presence of > 3 B-lines in two or more bilateral zones is highly suggestive of pulmonary oedema.

The "Relative Hypovolaemia" Pearl: Many patients present with acute pulmonary oedema due to fluid redistribution (driven by sympathetic surge) rather than total body fluid overload. These "warm and wet" hypertensive patients often require more vasodilators (GTN) than high-dose diuretics.

The "S3 Gallop" Pearl: An S3 heart sound has high specificity (> 90%) for elevated left ventricular end-diastolic pressure in AHF, although its sensitivity is low.

The "Early GDMT" Pearl: The STRONG-HF trial demonstrated that rapid up-titration of GDMT (SGLT2i, ARNI/ACEi, Beta-blocker, MRA) within 2 weeks of an AHF admission significantly reduces 180-day mortality and HF readmission.

---

2. Epidemiology

Incidence & Prevalence

• General: AHF accounts for 1-2% of all emergency hospital admissions in Western countries.
• Hospitalization: Approximately 5% of patients admitted to a general medical ward have AHF as the primary diagnosis.
• Recurrence: 20-30% of patients are readmitted within 30 days of discharge.

Demographics

• Age: Median age of presentation is 70-75 years.
• Sex: Roughly equal distribution, though women are more likely to present with Heart Failure with Preserved Ejection Fraction (HFpEF) and men with Heart Failure with Reduced Ejection Fraction (HFrEF).
• Ethnicity: Black populations have a higher incidence of AHF at a younger age, often driven by hypertensive heart disease.

Secondary Causes & Precipitants

Beyond the immediate "CHAMPIT" life-threats, other precipitants include:

• Anaemia: High-output failure or reduced oxygen delivery. Causes compensatory increase in CO which the failing heart cannot sustain.
• Thyroid Disease:
  • Thyrotoxicosis: Increases heart rate and contractility, often leading to "high-output" failure and tachycardia-induced cardiomyopathy.
  • Myxoedema: Associated with bradycardia, pericardial effusions, and reduced contractility.
• Alcohol/Toxins: Direct myocardial toxicity (e.g., cocaine, methamphetamines, certain chemotherapy agents like Anthracyclines or Trastuzumab).
• Sleep Apnoea: Obstructive sleep apnoea (OSA) generates high negative intrathoracic pressures during inspiration against a closed airway, which increases LV transmural pressure and afterload.
• Non-Adherence: The most common precipitant in many urban populations. Salt/fluid indiscretion often follows holiday periods.
• Progression of Underlying Disease: Gradual remodeling leading to a tipping point.

Risk Factors & Comorbidities (Expanded)

---

3. Pathophysiology

Molecular & Cellular Mechanisms

Step 1: Cardiomyocyte Injury & Dysfunction

In the acute phase, cardiomyocyte stress leads to several molecular derangements:

• Calcium Handling: Dysfunction of the SERCA2a (Sarco/endoplasmic reticulum Ca2+-ATPase) pump leads to delayed calcium reuptake into the sarcoplasmic reticulum. This results in impaired diastolic relaxation (lusitropy) and elevated cytosolic calcium, which can trigger arrhythmias.
• Myofilament Sensitivity: Alterations in the phosphorylation of Troponin I and Myosin Binding Protein C reduce the sensitivity of myofilaments to calcium, further depressing contractility.
• Mitochondrial Dysfunction: Reduced ATP production and increased reactive oxygen species (ROS) production lead to further contractile failure and potential apoptosis of cardiomyocytes.
• Troponin Release: Even in the absence of epicardial coronary occlusion, wall stress leads to subendocardial ischaemia and measurable troponin elevations (Type 2 Myocardial Infarction).

Step 2: Neurohormonal Activation (The "Vicious Cycle")

Reduced cardiac output or perceived "underfilling" triggers a massive neurohormonal response:

1. Sympathetic Nervous System (SNS): Norepinephrine release causes tachycardia (increasing oxygen demand), peripheral vasoconstriction (increasing afterload), and direct toxic effects on cardiomyocytes.
2. Renin-Angiotensin-Aldosterone System (RAAS): Angiotensin II causes potent vasoconstriction and stimulates Aldosterone, leading to sodium and water retention. Angiotensin II also promotes myocardial fibrosis.
3. Natriuretic Peptides (BNP/ANP): While the heart attempts to compensate by releasing BNP (which causes vasodilation and natriuresis), the system is overwhelmed by the SNS and RAAS activity. The Neprilysin enzyme degrades these beneficial peptides, a process now targeted by ARNI therapy.
4. Vasopressin (ADH): Released from the posterior pituitary, it leads to free water retention and further hyponatraemia, a marker of severe disease.

Step 3: Frank-Starling Relationship & Hemodynamics

The Frank-Starling mechanism states that the heart's stroke volume increases in response to an increase in the volume of blood filling the heart (end-diastolic volume), as the stretching of the cardiac muscle fibers increases the force of contraction.

• The Failing Curve: In AHF, the Frank-Starling curve is shifted downwards and to the right.
• The Plateau: Unlike a healthy heart, the failing heart reaches a plateau early. Further increases in preload (LVEDP) do not increase stroke volume but result in a steep rise in pulmonary capillary wedge pressure (PCWP).
• The Descending Limb: In extreme cases, over-stretching of the sarcomeres may actually lead to a reduction in stroke volume, though this is debated in clinical settings (the "over-distension" theory).
• Clinical Application: This is why "fluid challenges" must be extremely cautious in HF patients; they are already operating on the flat part of the curve.

Step 4: Molecular Cardiomyocyte Injury (The "AHF Cell")

At the cellular level, several pathways contribute to the "stunning" or "hibernation" of the myocardium in the acute setting:

1. Oxidative Stress: Overproduction of Superoxide and Peroxynitrite leads to DNA damage and lipid peroxidation.
2. Cytokine Activation: TNF-alpha and IL-6 are upregulated. TNF-alpha has direct negative inotropic effects by inhibiting calcium transients.
3. Adrenergic Desensitization: Chronic sympathetic surge leads to down-regulation of Beta-1 receptors and uncoupling of G-proteins. This explains why AHF patients may be less responsive to endogenous or exogenous catecholamines.
4. Sarcomere Disarray: Acute wall stress can lead to Z-disk disruption and degradation of Titin, the protein responsible for passive elasticity.

Step 5: The Cardiorenal Syndrome (CRS)

• Type 1 CRS: Acute HF leading to AKI.
• Mechanism: Driven by high venous pressure (renal congestion) rather than low arterial pressure. This "congestive AKI" often improves with aggressive diuresis despite transient rises in creatinine.
• Neurohormonal Cross-talk: Reduced cardiac output triggers RAAS, which further impairs renal function via efferent arteriolar constriction.

Step 6: The "Gut-Heart" Axis & Systemic Inflammation

• Congestion of the Gut Wall: Leads to increased permeability (leaky gut).
• Endotoxaemia: Translocation of lipopolysaccharides (LPS) from gut bacteria into the circulation.
• Inflammatory Surge: LPS triggers cytokine release (TNF-alpha, IL-6), contributing to myocardial depression and peripheral vasodilation (contributing to a "cold" profile).

Step 7: Venous Congestion & Organ Dysfunction

• Hepatic Congestion: "Nutmeg liver" appearance. Can lead to "cardiac cirrhosis" in chronic cases.
• Pulmonary Lymphatic Overload: Initial compensation via increased lymphatic drainage; once overwhelmed, alveolar oedema occurs.

---

4. Clinical Presentation

Symptoms

• Dyspnoea: Rapid onset, often at rest.
• Orthopnoea: Difficulty breathing when lying flat (highly specific for HF).
• Paroxysmal Nocturnal Dyspnoea (PND): Waking up gasping for air 1-2 hours after falling asleep.
• Bendopnoea: Shortness of breath when leaning forward (e.g., tying shoelaces).
• Reduced Exercise Tolerance: Fatigue and lethargy.

Signs

• Tachypnoea: RR > 20/min.
• Crepitations (Crackles): Typically fine, bibasal, but can be widespread in severe oedema.
• Peripheral Oedema: Pitting oedema in the ankles, shins, or sacrum (if bedbound).
• Raised JVP: Reflects elevated right atrial pressure.
• Hepatojugular Reflux: Positive if JVP rises > 3cm with RUQ pressure.

Red Flags

• Hypotension (SBP less than 90 mmHg): Suggests cardiogenic shock.
• Cold, Clammy Extremities: Signs of low cardiac output/poor perfusion.
• Oliguria (less than 0.5 mL/kg/hr): Reflects renal hypoperfusion.
• Altered Mental Status: Cerebral hypoperfusion.

Differential Diagnosis

• Respiratory: COPD/Asthma exacerbation, Pneumonia, Pulmonary Embolism, Pneumothorax.
• Cardiac: Myocardial Infarction, Pericardial Tamponade.
• Systemic: Severe Anaemia, Sepsis, Anxiety/Panic Attack.

---

5. Clinical Examination

Inspection

• Work of Breathing: Use of accessory muscles, intercostal recession.
• Cyanosis: Peripheral (low output) or central (hypoxaemia).
• Positioning: Patient prefers to sit upright and lean forward.

Palpation

• Apex Beat: Displaced (suggesting cardiomegaly) or heaving (pressure overload).
• Peripheries: Assess temperature (warm vs. cold). Cold peripheries suggest a "Cold" profile (hypoperfusion).
• Pulsus Alternans: Alternating strong and weak pulses; pathognomonic for severe LV dysfunction.

Auscultation

• Heart Sounds:
  • S3 (Ventricular Gallop): Low-frequency sound in early diastole. Suggests volume overload.
  • S4 (Atrial Gallop): Suggests stiff, non-compliant ventricle (common in HFpEF).
• Murmurs: Look for new pansystolic murmur (mitral regurgitation or VSD).
• Lung Sounds: Inspiratory crackles, often accompanied by expiratory wheeze ("Cardiac Asthma").

---

6. Investigations

Bedside

• ECG: Rarely normal in AHF. Look for ischaemia (ST changes), arrhythmias (AF), or evidence of chronicity (LVH, LBBB).
• Point-of-Care Ultrasound (POCUS):
  • Lung Ultrasound: Look for B-lines (vertical "comet tails").
  • IVC Ultrasound: Dilated, non-collapsing IVC suggests high right-sided pressures.
• Pulse Oximetry: Assess for hypoxaemia.

Bloods

• Natriuretic Peptides (BNP/NT-proBNP):
  • NT-proBNP less than 300 pg/mL or BNP less than 100 pg/mL makes AHF highly unlikely (High Negative Predictive Value).
  • Thresholds for inclusion are age-dependent (e.g., NT-proBNP > 450 if less than 55y, > 900 if 55-75y, > 1800 if > 75y).
• Troponin: Often elevated due to wall stress. Rising/falling pattern suggests ACS.
• U&Es: Assess for renal impairment (cardiorenal syndrome) and baseline potassium.
• Liver Function: "Congestive hepatopathy" can elevate transaminases and bilirubin.
• Lactate: Elevated in cardiogenic shock (metabolic acidosis).

Imaging

• Chest X-Ray:
  • Stage 1 (Redistribution): PCWP 13-18 mmHg. Upper lobe diversion (Stag's horn sign).
  • Stage 2 (Interstitial Oedema): PCWP 18-25 mmHg. Kerley B lines (short horizontal lines at the periphery), peribronchial cuffing, and hazy hila.
  • Stage 3 (Alveolar Oedema): PCWP > 25 mmHg. Bat's wing opacities (perihilar consolidation with peripheral sparing).
  • Pleural Effusions: Usually bilateral; if unilateral, more common on the right.
• Echocardiography (TTE): Mandatory within 48 hours (or urgently if shock/mechanical complication suspected).
  • Assess Ejection Fraction (LVEF): HFrEF (less than 40%), HFmrEF (41-49%), HFpEF (> 50%).
  • Filling Pressures: E/e' ratio > 14 suggests elevated LAP.
  • Valvular Pathology: Acute MR, AR, or stenosis.
• CT Thorax: Sometimes performed if PE is a differential; can show incidental pulmonary congestion and ground-glass opacities.

---

7. Management

Management Algorithm (Clinical Profile Approach)

                      ┌─────────────────────────────────────────┐
                      │      ACUTE HEART FAILURE SUSPECTED      │
                      └────────────────────┬────────────────────┘
                                           │
          ┌────────────────────────────────┴────────────────────────────────┐
          ▼                                                                 ▼
 ┌─────────────────┐                                               ┌─────────────────┐
 │ EMERGENCY PHASE │                                               │ DIAGNOSTIC WORK │
 │ • Oxygen if SpO2│                                               │ • ECG, BNP, CXR │
 │   less than 90% / NIV    │                                               │ • Point-of-Care │
 │ • Loop Diuretic │                                               │   Ultrasound    │
 │ • Vasodilators  │                                               │ • Bloods/Trops  │
 └────────┬────────┘                                               └────────┬────────┘
          │                                                                 │
          └────────────────────────────────┬────────────────────────────────┘
                                           │
                                           ▼
                      ┌─────────────────────────────────────────┐
                      │    IDENTIFY PRECIPITANTS (CHAMPIT)      │
                      │ C: ACS  H: Hypertensive Crisis          │
                      │ A: Arrhythmia  M: Mechanical Cause      │
                      │ P: Pulmonary Embolism  I: Infection     │
                      │ T: Tamponade                            │
                      └────────────────────┬────────────────────┘
                                           │
                                           ▼
                      ┌─────────────────────────────────────────┐
                      │      DEFINE CLINICAL PROFILE            │
                      └────────┬────────────────────────┬───────┘
                               ▼                        ▼
                    ┌──────────────────┐      ┌──────────────────┐
                    │  WET (Congested) │      │  DRY (Normal)    │
                    └────────┬─────────┘      └────────┬─────────┘
            ┌────────────────┴───────────────┐         │
            ▼                                ▼         ▼
    ┌──────────────┐                 ┌──────────────┐ ┌──────────────┐
    │     WARM     │                 │     COLD     │ │   WARM/DRY   │
    │(Well Perfused)│                 │(Hypoperfused)│ │  (Stable)    │
    └───────┬──────┘                 └───────┬──────┘ └───────┬──────┘
            │                                │                │
    ┌───────┴──────┐                 ┌───────┴──────┐ ┌───────┴──────┐
    │1. Diuretics  │                 │1. Inotropes  │ │1. Optimize   │
    │2. Vasodilator│                 │2. Diuretics  │ │   GDMT       │
    │3. NIV if P.O.│                 │3. Consider MCS│ │2. Discharge? │
    └──────────────┘                 └──────────────┘ └──────────────┘

1. The "Wet and Warm" Profile (Most Common)

• Primary goal: Decongestion and afterload reduction.
• Diuretics: IV Loop Diuretics (e.g., Furosemide 40-80mg or 2x the home dose). Monitor urine output (aim > 100mL/hr in the first 2 hours).
• Vasodilators: IV Glyceryl Trinitrate (GTN) or Isosorbide Dinitrate if SBP > 110 mmHg.
  • Dose: Start GTN at 10-20 mcg/min, titrate up to 200 mcg/min as tolerated.
• Non-Invasive Ventilation (NIV): CPAP (5-10 cmH2O) or BiPAP for patients with respiratory distress and pulmonary oedema. Reduces work of breathing and reduces preload/afterload.
• The "Diuretic Resistance" Strategy:
  • If inadequate response to loop diuretics, add Acetazolamide (500mg IV) or a Thiazide (e.g., Metolazone) to achieve "sequential nephron blockade."

2. The "Wet and Cold" Profile (Cardiogenic Shock)

• Primary goal: Restore perfusion (MAP > 65 mmHg) AND decongest.

• Hemodynamic Monitoring: Consider an Arterial Line for continuous BP monitoring and a Central Venous Catheter.

• Inotropes & Vasopressors Table: | Agent | Mechanism | Dose | Clinical Consideration | |-------|-----------|------|------------------------| | Dobutamine | Beta-1 & Beta-2 agonist | 2.5–20 mcg/kg/min | First-line inotrope. May cause tachycardia and drop SBP (B2 effect). | | Milrinone | PDE3 inhibitor | 0.375–0.75 mcg/kg/min | Increases CO and reduces afterload. Longer half-life (caution in renal failure). | | Norepinephrine| Alpha-1 > Beta-1 agonist | 0.05–0.5 mcg/kg/min | Preferred vasopressor to maintain MAP. | | Levosimendan | Calcium sensitizer | 0.05–0.2 mcg/kg/min | No increase in O2 demand. Long-acting metabolites (up to 1 week). | | Adrenaline | Alpha and Beta agonist | 0.05–0.5 mcg/kg/min | Second-line for refractory shock; highly pro-arrhythmic. |

• Caution: Diuretics should be delayed until perfusion is improved (MAP > 65 mmHg) to avoid worsening AKI.

3. The "Dry and Cold" Profile

• Primary goal: Restore volume and exclude other causes of shock (Sepsis, Bleeding).
• Fluid Challenge: Small boluses (250mL) of crystalloid (e.g., Hartmann's), with frequent lung auscultation and JVP assessment.
• Hemodynamic Targets: Aim for a CVP of 8-12 mmHg.
• Transition: Often these patients move to "Warm and Dry" or may have a different diagnosis (e.g., occult bleeding in a patient on anticoagulants).

4. Advanced Therapies & Mechanical Circulatory Support (MCS)

• Intra-Aortic Balloon Pump (IABP):
  • Mechanism: Inflation in diastole (augments coronary flow), deflation in systole (reduces afterload).
  • Indications: Mechanical complications of MI (VSD, MR), bridge to intervention in ACS.
• Impella (2.5, CP, 5.0):
  • Mechanism: Axial flow pump across the aortic valve.
  • Benefit: Actively unloads the LV, reducing wall stress and O2 consumption.
• Extracorporeal Membrane Oxygenation (VA-ECMO):
  • Mechanism: Pumps blood from venous system, oxygenates it, and returns it to the arterial system.
  • Risk: Increases LV afterload ("North-South Syndrome"). May require "venting" with IABP or Impella (ECMELLA).
• Left Ventricular Assist Device (LVAD): Durable support for patients who cannot be weaned from temporary MCS.

5. Palliative Care & Symptom Control

• Dyspnoea: Low-dose oral/SC morphine (2.5mg - 5.0mg) is effective for air hunger.
• Anxiety: Benzodiazepines (e.g., Lorazepam) for acute distress.
• Communication:
  • Clarify goals of care early.
  • Discuss the deactivation of ICDs (Implantable Cardioverter Defibrillators) in the terminal phase to avoid painful shocks.
  • Involve the multi-disciplinary team (MDT) including HF nurses and palliative specialists.

6. Discharge Optimization (STRONG-HF Strategy)

• Initiation of the "Four Pillars" before discharge:
  1. SGLT2i (Dapagliflozin or Empagliflozin).
  2. MRA (Spironolactone or Eplerenone).
  3. Beta-blocker (Bisoprolol, Carvedilol, or Metoprolol succinate).
  4. ARNI (Sacubitril/Valsartan) or ACEi.
• Close follow-up within 1 week of discharge.

---

8. Complications

• Cardiorenal Syndrome (Type 1): Acute worsening of renal function (rise in Creatinine > 26 μmol/L or > 50% from baseline). Driven primarily by renal venous hypertension ("congestive AKI") and increased intra-abdominal pressure, rather than low cardiac output.
• Cardiohepatic Syndrome:
  • Congestive Hepatopathy: Elevated Bilirubin, GGT, and ALP due to passive congestion. Can lead to "Cardiac Cirrhosis" in chronic states.
  • Ischaemic Hepatitis (Shock Liver): Massive elevation of ALT/AST (> 1000) following a period of profound hypotension and hypoperfusion.
• Arrhythmias:
  • Atrial Fibrillation (AF): Present in 30-40% of AHF patients; often both a cause and a consequence of decompensation.
  • Ventricular Arrhythmias: VT/VF risk is heightened by myocardial wall stress, electrolyte imbalances (hypokalaemia/hypomagnesaemia), and SNS surge.
• Thromboembolism: High risk of DVT/PE due to stasis and systemic inflammation. Mural thrombus is a risk in patients with large areas of wall motion abnormality (e.g., anterior MI).
• Respiratory Complications: Pleural effusions (typically transudative), respiratory muscle fatigue leading to Type 2 respiratory failure, and ventilator-associated pneumonia (if intubated).
• Sarcopenia & Cardiac Cachexia: Rapid loss of lean muscle mass and fat tissue driven by a catabolic state, TNF-alpha activation, and reduced nutrient absorption due to gut oedema.
• Iatrogenic Complications:
  • Electrolyte Derangements: Hypokalaemia and hyponatraemia from aggressive diuresis.
  • Ototoxicity: Rare but possible with high-dose IV loop diuretics.
  • Line-associated Infections: From central venous catheters or arterial lines.

---

9. Prognosis

• In-Hospital Mortality: Historically 4-10%, but remains as high as 40-50% for those presenting in cardiogenic shock.
• The "Revolving Door" Phenomenon: 25% of patients are readmitted within 30 days, and 50% within 6 months. Each hospitalization is a marker of disease progression and is associated with a permanent loss of functional reserve.
• Functional Trajectory: Post-discharge, many patients do not return to their baseline NYHA functional class, leading to a "downward stair-step" decline in quality of life.

Risk Scoring Systems

• GWTG-HF Score (Get With The Guidelines): Validated tool using age, SBP, BUN, heart rate, race, presence of COPD, and admission Creatinine to predict in-hospital mortality.
• MAGGIC Score: A comprehensive meta-analysis derived score that predicts 1-year and 3-year mortality across the spectrum of HFrEF and HFpEF.
• Seattle Heart Failure Model: Predicts survival based on clinical, laboratory, and medication variables, and can model the impact of adding specific GDMT agents.

Key Predictors of Poor Outcome

• Clinical Indicators: Persistent S3 gallop, SBP less than 90 mmHg on admission, NYHA Class IV symptoms at baseline, and significant frailty.
• Laboratory Biomarkers:
  • Sodium: Hyponatraemia (less than 135 mmol/L) is a potent marker of neurohormonal activation and poor prognosis.
  • BUN: Elevated Blood Urea Nitrogen (> 15 mmol/L) reflects both renal congestion and low flow.
  • NT-proBNP: Higher absolute values and failure to reduce by > 30% during admission are associated with high mortality.
  • Troponin: Persistent low-level leak indicates ongoing cardiomyocyte injury.
• Comorbidities: Chronic Kidney Disease (CKD), Anaemia, Diabetes Mellitus, and Obstructive Sleep Apnoea.

---

10. Evidence & Guidelines

Key Guidelines

• ESC 2021 Heart Failure Guidelines: Focused on the CHAMPIT mnemonic and clinical profiles. Introduced the 4-pillar GDMT as Class I.
• ESC 2023 Focused Update: Emphasized the "Triple Therapy" (SGLT2i, MRA, Beta-blocker/ARNI) should be started before discharge (Class I recommendation). Added specific recommendations for SGLT2i in HFpEF and HFmrEF.
• ACC/AHA 2022 Guidelines: Similar emphasis on early GDMT and the use of SGLT2 inhibitors. Defined "Pre-HF" (Stage B) and "Advanced HF" (Stage D) more clearly.
• NICE NG204 (2018/2023): UK guidelines emphasizing multi-disciplinary care, cardiac rehabilitation, and specific thresholds for specialist referral.

The Evolution of Management

The management of AHF has shifted from a "reactive" model focused solely on diuresis to a "proactive" model focused on early neurohormonal modulation. Historically, clinicians waited until the patient was "stable and dry" before starting GDMT. However, trials like PIONEER-HF and STRONG-HF have proven that starting these life-saving therapies while the patient is still hospitalized is not only safe but significantly more effective at preventing the "vicious cycle" of readmission.

Landmark Trials

---

11. Patient Explanation

What is Acute Heart Failure?

"Think of your heart as a pump and your blood vessels as a series of pipes. In heart failure, the pump isn't working at full strength. In this 'acute' stage, the pump has suddenly slowed down, causing fluid to 'back up' into your lungs—much like a blocked sink. This is why you feel so breathless. It is not that your lungs are sick, but rather that they are being flooded from the back-pressure of the heart."

Why did this happen?

"It could be due to a sudden change in heart rhythm, a new problem with a heart valve, or even an infection that put too much stress on your heart. Sometimes, it's because the heart needs an adjustment in the medicines you take, or perhaps a previous heart attack has left the muscle weaker than we realized."

How will we treat it?

"Our first goal is to remove the extra fluid. We will give you a strong 'water pill' (diuretic) through a vein to help your kidneys flush out the excess. We might also give you oxygen or a special breathing mask (NIV) to help push the fluid out of your lungs so you can breathe easier. Once you are stable, we will start 'heart-protective' medicines—the 'four pillars'—that will help your heart pump more efficiently and keep you out of the hospital in the future."

What happens next?

"Heart failure is a journey, not a single event. Before you go home, we will make sure your dose of medicine is as high as you can safely tolerate. You will need close follow-up with our heart failure specialist nurses to ensure your heart stays as strong as possible."

---

12. References

1. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42:3599-3726. PMID: 34447992.
2. Mullens W et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44:3627-3639. PMID: 37622666.
3. Heidenreich PA et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022; 145:e895-e1032. PMID: 35363499.
4. Felker GM et al. Diuretic strategies in patients with acute decompensated heart failure (DOSE). N Engl J Med. 2011; 364:797-805. PMID: 21345102.
5. Morrow DA et al. Sacubitril/Valsartan in Patients Hospitalized with Acute Decompensated Heart Failure (PIONEER-HF). N Engl J Med. 2019; 380:539-548. PMID: 30415606.
6. Voors AA et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (EMPULSE). Nat Med. 2022; 28:568-574. PMID: 35228754.
7. Mebazaa A et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). Lancet. 2022; 400:1938-1952. PMID: 36368344.
8. Mullens W et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR). N Engl J Med. 2022; 387:1185-1195. PMID: 36043141.
9. Teerlink JR et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure (GALACTIC-HF). N Engl J Med. 2021; 384:105-116. PMID: 33185995.
10. Cox ZL et al. Dapagliflozin in patients with acute heart failure: A randomized, double-blind, placebo-controlled, multicenter trial (DAPA-RESIST). Eur Heart J. 2023. PMID: 36814324.
11. Trullàs JC et al. Combined diuretic therapy with thiazides in acute heart failure (CLOROTIC). Eur Heart J. 2022. PMID: 36190858.
12. Pitt B et al. Patiromer to enable RAASi in patients with heart failure and reduced ejection fraction and a history of hyperkalemia (DIAMOND). Eur Heart J. 2022. PMID: 35370425.
13. Metra M et al. The role of serial NT-proBNP measurements in the management of heart failure. JACC. 2021.
14. Yancy CW et al. Clinical Practice Guideline: Advanced Heart Failure. Circulation. 2022.
15. Greene SJ et al. The Forgotten Patient: Heart Failure with Preserved Ejection Fraction. JAMA Cardiology. 2023.
16. Lindenfeld J et al. COAPT Trial: Transcatheter Mitral-Valve Repair in Heart Failure. N Engl J Med. 2018; 379:2307-2318.
17. Packer M et al. SGLT2 inhibitors and the treatment of heart failure: a consensus statement. Lancet. 2023.
18. Bozkurt B et al. Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure. 2021.
19. Januzzi JL et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure (PRIDE study). Am J Cardiol. 2005; 95:948-954.
20. Masip J et al. Non-invasive ventilation in acute cardiogenic pulmonary edema. JAMA. 2005; 294:3124-3130.

---

13. Examination Focus

OSCE Station: Acute Heart Failure Management

Scenario: "A 75-year-old female presents to A&E with severe SOB and orthopnoea. Her BP is 160/90, HR 110 (irregular), SpO2 88% on air." Task: Initial assessment and management plan. Checklist:

1. ABCDE: Sit patient upright, high-flow O2.
2. Immediate Rx: IV Furosemide (e.g., 80mg). Consider GTN infusion for hypertension.
3. Investigations: ECG (likely AF), CXR, Bedside Echo/Lung US, BNP, Troponin.
4. Precipitants: CHAMPIT (Is this AF with RVR? Is it an MI?).
5. Disposition: Escalation to CCU/ITU if NIV required or SBP drops.

Viva Questions

1. "What is the mechanism of action of SGLT2 inhibitors in AHF?"
   • They promote osmotic diuresis and natriuresis (by blocking glucose/sodium reuptake in the proximal convoluted tubule) without stimulating the RAAS. They also improve myocardial energy metabolism by shifting fuel utilization toward ketones, reduce oxidative stress, and decrease systemic inflammation.
2. "Explain the CHAMPIT mnemonic and its clinical utility."
   • It stands for Coronary syndrome (ACS), Hypertensive emergency, Arrhythmia, Mechanical cause (e.g., VSD), Pulmonary embolism, Infection, and Tamponade. It is used in the first 60-120 minutes of AHF presentation to rapidly identify and treat reversible life-threats.
3. "How do you distinguish between HFpEF and HFrEF in the acute setting?"
   • Clinically they are often identical; the distinction is made by Echocardiography (EF > 50% vs less than 40%). NT-proBNP levels are typically lower in HFpEF than HFrEF for a given degree of congestion. HFpEF patients are often older, female, and have more hypertension/AF.
4. "When would you use an inotrope in AHF?"
   • Only in the presence of cardiogenic shock (hypoperfusion + hypotension). Routine use in non-shocked patients increases mortality due to increased myocardial oxygen demand and pro-arrhythmic effects. Inotropes like Dobutamine should be considered "bridge" therapies.
5. "What is the significance of the STRONG-HF trial?"
   • It proved that intensive, rapid up-titration of GDMT (SGLT2i, MRA, Beta-blocker, ARNI/ACEi) started before discharge and monitored closely post-discharge (reaching 100% of target doses by 2 weeks) reduces 180-day mortality and HF readmission.
6. "What is 'congestive AKI' and how do you manage it?"
   • AKI driven by high renal venous pressure and interstitial oedema (Type 1 Cardiorenal Syndrome). Paradoxically, it is managed by increasing diuresis to reduce venous pressure, which improves renal perfusion. This is the "Goldilocks" principle of renal perfusion in HF.
7. "What are the indications for Mechanical Circulatory Support in AHF?"
   • Bridge to recovery (e.g., fulminant myocarditis), bridge to decision (stabilizing the patient to assess prognosis), or bridge to transplant/LVAD. It is indicated in refractory cardiogenic shock despite inotropes.
8. "Why is morphine no longer recommended as routine treatment for AHF?"
   • Retrospective studies (like Midas) suggest it is associated with a higher rate of intubation, ICU admission, and mortality (due to respiratory depression and masking of symptoms). It should be reserved for palliative symptom relief only.
9. "What is the role of the 'Third Pillar' in AHF (MRA)?"
   • MRAs like Spironolactone reduce fibrosis and prevent potassium loss during aggressive diuresis. The ATHENA-HF trial studied high-dose MRA but did not show significant benefit over low-dose in the acute phase; however, long-term mortality benefit is class-leading.
10. "How do you manage a patient with 'diuretic resistance'?"
    • Ensure IV delivery, increase loop dose (e.g., to 2.5x oral dose), add a second agent for sequential nephron blockade (Acetazolamide, Metolazone, or SGLT2i), and consider ultrafiltration if refractory.
11. "What is the 'Flash Pulmonary Oedema' and how does its management differ?"
    • Sudden onset oedema usually due to hypertensive crisis or acute ischaemia. The primary problem is fluid redistribution rather than total body overload. Management prioritizes rapid afterload reduction (IV GTN) over aggressive diuresis.
12. "What is the significance of 'Bendopnoea'?"
    • Shortness of breath when leaning forward (e.g., to tie shoelaces). It is a sign of high filling pressures and is associated with poor prognosis and higher PCWP.
13. "How do you interpret a 'wet and cold' patient with a low SBP but high systemic vascular resistance (SVR)?"
    • This patient has severe LV failure and compensatory vasoconstriction. They need inotropes to increase CO and potentially vasodilators (if BP allows) or MCS to reduce the SVR and unload the LV.
14. "What are the target doses for the 'Four Pillars' in HFrEF?"
    • Sacubitril/Valsartan 97/103mg BD, Bisoprolol 10mg OD, Spironolactone 50mg OD, Empagliflozin 10mg OD. The goal of STRONG-HF was to reach these (or max tolerated) rapidly.
15. "Describe the 'ASAP' approach to AHF in the Emergency Department."
    • Assess (Airway, Breathing, Perfusion), Stabilize (O2, NIV, Diuretics), Analyze (ECG, Bloods, POCUS, CXR), Plan (Identify precipitant, decide disposition).
16. "What is the 'B-line' sign on lung ultrasound?"
    • Vertical, hyperechoic 'comet-tail' artifacts arising from the pleural line. > 3 B-lines in 2+ bilateral zones suggests interstitial/alveolar fluid with 90% sensitivity for AHF.
17. "Define the 'North-South' syndrome in VA-ECMO."
    • Occurs when the heart begins to recover but the lungs are still sick. Deoxygenated blood from the heart reaches the upper body (brain/arms), while oxygenated blood from the ECMO only reaches the lower body.
18. "What is the prognostic value of NT-proBNP reduction?"
    • A reduction of > 30% in NT-proBNP from admission to discharge is associated with significantly better outcomes and lower readmission rates.
19. "How does the management of RV failure differ from LV failure?"
    • RV failure is highly preload-dependent; avoid excessive diuretics or nitrates. Inotropes (Milrinone) and reducing pulmonary vascular resistance (inhaled NO) are prioritized.
20. "What is the 'Worsening Heart Failure' (WHF) definition?"
    • An escalation of HF symptoms/signs requiring a change in therapy (typically IV diuretics) in a patient already on chronic HF treatment, either as an outpatient or inpatient.

Top 5 Board Exam Facts

1. Hyponatraemia in AHF is a marker of severe RAAS and ADH activation; it is an independent predictor of mortality.
2. SGLT2 inhibitors are the only class of GDMT with a Class I recommendation for initiation in all AHF patients regardless of ejection fraction (HFrEF, HFmrEF, and HFpEF).
3. Nitroglycerin (GTN) should be avoided in patients with right ventricular infarction (preload dependent) or those taking PDE5 inhibitors (e.g., Sildenafil) due to the risk of profound hypotension.
4. NT-proBNP has a high negative predictive value (> 95%) for ruling out AHF in the acute setting but can be "falsely" low in obese patients and "falsely" high in those with CKD or AF.
5. Beta-blockers should generally be continued during an AHF admission unless the patient is in cardiogenic shock (Cold profile) or has high-grade AV block.

Self-Assessment Question

Question: A 68-year-old male with known HFrEF (LVEF 30%) is admitted with 3 days of worsening SOB and peripheral oedema. His BP is 105/70 mmHg, HR 92 bpm, and peripheries are warm. Laboratory tests show a Creatinine of 145 μmol/L (baseline 110) and Potassium of 4.8 mmol/L. What is the most appropriate next step in his management?

• A) Start Dobutamine infusion.
• B) Give IV Furosemide bolus (2.5x home dose).
• C) Start IV Norepinephrine to maintain renal perfusion.
• D) Withhold all diuretics due to rising Creatinine.

Answer: B. This patient has a "Warm and Wet" profile. The rising Creatinine likely reflects "congestive AKI" (Type 1 Cardiorenal Syndrome), which often improves with effective diuresis. Inotropes (A) are not indicated in a "Warm" patient. Vasopressors (C) are for shock. Withholding diuretics (D) will worsen the renal congestion.

---

Last Reviewed: 2026-01-04 | MedVellum Editorial Team